A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02014480 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE: Umeclidinium 62.5 mcg
DEVICE: Vilanterol 25 mcg
DEVICE: Umeclidinium/Vilanterol 62.5/25 mcg

Sponsor

GlaxoSmithKline